Re:Search Institution Members

150 Results for Members


Makerere University has a focused, multi-disciplinary research agenda that includes research projects spanning...

The Association of University Technology Managers (AUTM) is a non-profit organization dedicated to bringing...

The Bibliotheca Alexandrina is a major library and cultural center located in the Egyptian city of Alexandria....

Biotechnology Industry Organization (BIO) is the world's largest trade association representing biotechnology...

The Pasteur Institute is a French non-profit private foundation dedicated to the study of biology, micro...

IRSS is the national health sciences research institute in Burkina Faso.

160 Results for Collaborations


Investigators at the University of Melbourne and Monash University identified compounds that inhibit the barber’s pole worm, and were interested in screening them against other infectious worms. BVGH connected them with an investigator at University of Buea, who is developing inhibitors against Onchocerca. The University of Buea will screen the University of Melbourne compounds against Onchocerca volvulus to identify potential drug candidates.

Fidelis Cho-Ngwa is the Head of the Pan-African ANDI Centre of Excellence and Associate Professor of Biochemistry and Molecular Biology at the University of Buea in Cameroon. He has a strong interest in onchocerciasis research, given that more than 40% of Camerooonians sufer from that. Fidelis Cho-Ngwa aims at identifying active natural products to be used as drugs against Onchocerca worms. In 2013, he was invited to spend a three-month period at Novartis facilities in Based, Switzerland, where he could acquire in-depth knowledge and skills required to use high-performance liquid chromatography (HPLC) and mass spectrometry (MS) techniques to extract, purify, and identify the active compounds from natural products identified during a tripartite anti-onchocercal phenotypic screen.

Christian Agyare is a professor from the Department of Pharmaceutics of University of Ghana bioactive agents based on medicinal plants for their potential to treat infectious, including NTDs. In October 2013, Christian Agyare was invited to collaborate for a ten-month sabbatical with Conor Caffrey from the Center for Discovery and Innovation in Parasitic Diseases (CDIPD), University of California, San Francisco (UCSF). The purpose of the collaboration was to enhance Christian Agyare's experience in cultivating, maintaining and screening compounds against various parasitic organisms. As a result, he found that at least three hit compounds, fractions and extracts were identified for each parasites and worms.

Gertrude Kyere-Davies is a Master's student at Kwame Nkrumah University of Science and technology (KNUST) of the University of Ghana. She was invited at University of California, San Diego (UCSD), for continuing the research initiated by her professor Christian Agyare in 2013 at University of California, San Francisco (UCSF). The main purpose of her research was to screen various plant extracts and compounds against schistomes and other parasites, such as Trypanosoma cruzi, Leishmania, Trypanosoma brucei, Giardia lamblia and Entamoeba histolytica. The fellowship led to obtain hits that can be further worked on.

Krupa Naran is a postdoctoral fellow at the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa, collaborating with AstraZeneca on Tuberculosis. In particular, she meant investigating different procedures aimed at assessing the composition of a substance, in order to try to find out which would be the best drug to treat TB.

During her fellowship at the University of Melbourne with the host scientists Leanne Tilley and Matthew Dixon, Tahmina Ahmed from the International Center for Diarrheal Disease Research in Bangladesh (iccdr,b) investigated the antimalarial activity of two novel antimalarial compounds inhibitors. The compounds have been shown to have activity against enzymes that activate ubiquitin and ubiquitin-like proteins. Ms. Ahmed measured the anti-malarial activities of these drugs. This project investigated two drug candidates. Compound 1 proved more potent than chloroquine (IC50 59 nM) and artemisinin (IC50 4 nM). Antimalarial drugs that inhibit apicoplast biogenesis exhibit a delayed death mechanism of killing, however, both compounds 1 and 2 kill parasites rapidly.

172 Results for Assets


This invention describes the design and synthesis of a multi-peptide conjugate (MPC) system containing antigens from the human malaria parasite (Plasmodium falciparium) and the Tat protein of HIV type-1 (HIV-1-Tat) for use as a subunit vaccine. The current multiple peptide conjugates (MPCs) have distinct advantages over prior MAPs because only two adjacent peptide branches are elongated on the solid phase at either the alpha or epsilon amino groups thereby allowing maximum spacing between the resin bound peptide chains. These peptides are then reacted with high performance liquid chromatography purified haloacetyl peptides to generate multiple peptide conjugates with molecular masses of 10 to 13 kDa.
The pMOD plasmid will have utility in construction of transposons for use in genetic manipulation of Mycobacteria including M.tuberculosis. Previous methods for transposon mutagenesis of Mycobacteria were cumbersome and inefficient. The pMOD plasmid is an integral part of a transposition system that is technically easy and quite efficient. This plasmid will also likely be useful for genetic manipulation of other bacteria and fungi. It would therefore be a very useful tool for molecular biologic and genetic research involving these organisms.
Malaria is estimated to cause two to four million deaths per year, and 200 to 400 million people are infected annually with the deadliest of the protozoans that cause the disease, Plasmodium falciparum. The life cycle of the malarial parasite is very complex, involving stages that reside in both humans and mosquitoes. Vaccines that are able to inhibit the transmission of the disease at a variety of stages in the complex life cycle of the malarial parasite might provide an opportunity to effectively control and possible eradicate this disease. This invention relates to the generation of transmission-blocking antibodies to two sexual stage surface antigens, Pfs 25 and Pfs 28. Two issued patents cover the use of these antigens separately as transmission-blocking vaccines. The claims of the current invention relate to the production of fusion proteins between these two surface antigens that have increased potency as immunogens and ease of manufacture.
A series of Thalidomide analogs which exhibit inhibition of angiogenesis, NIH Internal Reference E-272-2003. The subject application discloses active thalidomide analogs that exhibit enhanced potency in the inhibition of undesirable angiogenesis, and methods for using these compounds to treat angiogenesis and solid tumors. In particular, the presently disclosed method provides for inhibiting unwanted angiogenesis in a human or animal by administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of the active thalidomide analogs. According to a more specific aspect, the method involves inhibiting angiogenesis by exposing a mass having the undesirable angiogenesis to an angiogenesis inhibiting amount of one or more compounds, or pharmaceutically acceptable salts of such compounds.
A synthetic vaccine is available for testing against P. falciparum malaria. Control of malarial disease has been achieved on a limited basis in certain parts of the world; however, no vaccine presently exists that can provide protective immunity. This synthetic vaccine contains a peptide which induces the activation of cytotoxic T cells that specifically recognize and kill cells infected with malaria sporozoites.
A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria.